Bagsværd, Denmark, 3 December 2012 – Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical ...

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 ...

HealthDay News — Two new diabetes treatments, Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), have been approved by the U.S. Food and Drug Administration.

Bagsværd, Denmark, 10 February 2013 - Novo Nordisk today announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug ...

COPENHAGEN (Reuters) - Novo Nordisk has launched its type 2 diabetes treatment Ryzodeg in Mexico, a combination drug that could reap the company billions in revenues in years to come. Ryzodeg combines ...

Bagsværd, Denmark, 26 March 2015 – Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug ...

Danish pharmaceutical company Novo Nordisk announced last week that its diabetes-fighting insulin drug Ryzodeg has been approved for sale in Japan by the Japanese Ministry of Health, Labour, and ...

today announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba ® (insulin degludec) and ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Danish drugmaker Novo Nordisk's diabetes drug Tresiba, two years after rejecting the long-acting form of insulin. The agency also ...

BAGSVÆRD, Denmark — The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday. Novo Nordisk said it received complete ...